Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

bioMérieux S.A.. (11/7/16). "Press Release: Pierre Boulud Appointed Corporate Vice President of the Asia Pacific Region at bioMérieux". Marcy l’Étoile.

Region Region Asia & Oceania
Organisation Organisation bioMérieux S.A. (Euronext: BIM)
  Group Mérieux (Group)
Products Product in vitro diagnostics (IVD)
  Product 2 pharmaceutical
Person Person Mérieux, Alexandre (bioMérieux 201404– CEO before VP Industrial Microbiology)
     


bioMérieux, a world leader in the field of in vitro diagnostics, has announced the appointment of Pierre Boulud to the position of Corporate VP in charge of the Asia Pacific region as of November 2. He joins the Executive Committee of bioMérieux and will report directly to Alexandre Mérieux, CEO.

Pierre Boulud will also be in charge of bioMérieux’s portfolio and strategic planning starting on January 1, 2017.

Before joining bioMérieux, Pierre Boulud worked for 14 years at Ipsen pharmaceutical company, where he held various positions, in particular as the head of the Department of Strategy and Business Development. Since 2013, he was Executive Vice President in charge of Specialty Care Commercial Operations. Before he joined Ipsen, he worked at the Boston Consulting Group where he was in charge of strategic consulting assignments for five years. Pierre Boulud began his career in 1995 at the consulting firm Bossard Consultants.

Representing 17% of bioMérieux’s total sales for the first nine months of 2016, with 12.2% year-on-year sales growth, the Asia Pacific region is a major driver of development for the Company.

Pierre Boulud holds a Master of Business Administration from ESSEC.


About bioMérieux
Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2015, bioMérieux’s revenues reached €1,965 million with 90% of international sales.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

(Symbol: BIM/Reuters: BIOX.PA/Bloomberg: BIM.FP – ISIN: FR0010096479).

Corporate website: www.biomerieux.com
Investor website: www.biomerieux-finance.com


Contacts

Investor Relations
bioMérieux
Sylvain Morgeau
Tel: + 33 4 78 87 22 37
investor.relations@biomerieux.com

Media Relations

bioMérieux
Aurore Sergeant
Tel: + 33 4 78 87 54 75
media@biomerieux.com

Image Sept
Laurence Heilbronn Claire Doligez
Tel: + 33 1 53 70 74 64 Tel: + 33 1 53 70 74 48
lheilbronn@image7.fr cdoligez@image7.fr

   
Record changed: 2016-12-23

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for Mérieux (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px